Stuttgart - Delayed Quote EUR
CARISMA Therapeutics Inc (W2J.SG)
0.1633
-0.0056
(-3.32%)
As of 8:02:42 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
19,632
19,632
14,919
9,834
--
Operating Expense
81,811
81,811
103,650
65,996
40,794
Operating Income
-62,179
-62,179
-88,731
-56,162
-40,794
Net Non Operating Interest Income Expense
1,702
1,702
1,936
-3,145
10
Other Income Expense
--
--
-84
-1,919
--
Pretax Income
-60,477
-60,477
-86,879
-61,226
-40,784
Net Income Common Stockholders
-60,477
-60,477
-86,879
-61,226
-40,784
Diluted NI Available to Com Stockholders
-60,477
-60,477
-86,879
-61,226
-40,784
Basic EPS
-1.46
--
-2.59
-1.52
-1.01
Diluted EPS
-1.46
--
-2.59
-1.52
-1.01
Basic Average Shares
41,456.2100
--
33,524.1970
40,254.6660
40,254.6660
Diluted Average Shares
41,456.2100
--
33,524.1970
40,254.6660
40,254.6660
Total Operating Income as Reported
-62,179
-62,179
-88,731
-56,162
-40,794
Total Expenses
81,811
81,811
103,650
65,996
40,794
Net Income from Continuing & Discontinued Operation
-60,477
-60,477
-86,879
-61,226
-40,784
Normalized Income
-60,477
-60,477
-86,795
-59,307
-40,784
Interest Income
1,702
1,702
1,936
--
10
Interest Expense
--
--
--
3,145
--
Net Interest Income
1,702
1,702
1,936
-3,145
10
EBIT
-62,179
-62,179
-88,731
-58,081
-40,794
EBITDA
-58,825
-58,825
-85,894
-56,188
-40,112
Reconciled Depreciation
3,354
3,354
2,837
1,893
682
Net Income from Continuing Operation Net Minority Interest
-60,477
-60,477
-86,879
-61,226
-40,784
Total Unusual Items Excluding Goodwill
--
--
-84
-1,919
--
Total Unusual Items
--
--
-84
-1,919
--
Normalized EBITDA
-58,825
-58,825
-85,810
-54,269
-40,112
12/31/2021 - 3/8/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade